WO2003027313A3 - SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - Google Patents

SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE Download PDF

Info

Publication number
WO2003027313A3
WO2003027313A3 PCT/US2002/030532 US0230532W WO03027313A3 WO 2003027313 A3 WO2003027313 A3 WO 2003027313A3 US 0230532 W US0230532 W US 0230532W WO 03027313 A3 WO03027313 A3 WO 03027313A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
suppressors
cpg oligonucleotides
administering
disclosed
Prior art date
Application number
PCT/US2002/030532
Other languages
French (fr)
Other versions
WO2003027313A2 (en
Inventor
Dennis M Klinman
Mayda Gursel
Ihsan Gursel
Rainald Zeuner
Daniela Verthelyi
Original Assignee
Us Gov Health & Human Serv
Dennis M Klinman
Mayda Gursel
Ihsan Gursel
Rainald Zeuner
Daniela Verthelyi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Dennis M Klinman, Mayda Gursel, Ihsan Gursel, Rainald Zeuner, Daniela Verthelyi filed Critical Us Gov Health & Human Serv
Priority to US10/489,839 priority Critical patent/US7514414B2/en
Priority to AU2002353783A priority patent/AU2002353783A1/en
Publication of WO2003027313A2 publication Critical patent/WO2003027313A2/en
Publication of WO2003027313A3 publication Critical patent/WO2003027313A3/en
Priority to US12/395,539 priority patent/US8227438B2/en
Priority to US13/530,028 priority patent/US8580944B2/en
Priority to US14/026,995 priority patent/US9163244B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Abstract

The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.
PCT/US2002/030532 2001-09-24 2002-09-24 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE WO2003027313A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/489,839 US7514414B2 (en) 2001-09-24 2002-09-24 Suppressors of CpG oligonucleotides and methods of use
AU2002353783A AU2002353783A1 (en) 2001-09-24 2002-09-24 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US12/395,539 US8227438B2 (en) 2001-09-24 2009-02-27 Suppressors of CpG oligonucleotides and methods of use
US13/530,028 US8580944B2 (en) 2001-09-24 2012-06-21 Suppressors of CpG oligonucleotides and methods of use
US14/026,995 US9163244B2 (en) 2001-09-24 2013-09-13 Suppressors of CpG oligonucleotides and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32448401P 2001-09-24 2001-09-24
US60/324,484 2001-09-24
US40082602P 2002-08-01 2002-08-01
US60/400,826 2002-08-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/619,949 Continuation-In-Part US8557789B2 (en) 2001-09-24 2012-09-14 Method of treating inflammatory arthropathies with supressors of CPG oligonucleotides

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/489,839 A-371-Of-International US7514414B2 (en) 2001-09-24 2002-09-24 Suppressors of CpG oligonucleotides and methods of use
US10489839 A-371-Of-International 2002-09-24
US12/395,539 Division US8227438B2 (en) 2001-09-24 2009-02-27 Suppressors of CpG oligonucleotides and methods of use

Publications (2)

Publication Number Publication Date
WO2003027313A2 WO2003027313A2 (en) 2003-04-03
WO2003027313A3 true WO2003027313A3 (en) 2004-01-08

Family

ID=26984484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/030532 WO2003027313A2 (en) 2001-09-24 2002-09-24 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE

Country Status (3)

Country Link
US (4) US7514414B2 (en)
AU (1) AU2002353783A1 (en)
WO (1) WO2003027313A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO2000061151A2 (en) * 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
EP1575504A4 (en) 2002-08-01 2009-11-04 Us Gov Health & Human Serv Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
EP2241325B1 (en) * 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP4673217B2 (en) * 2003-04-23 2011-04-20 由紀夫 佐藤 Methylated CpG polynucleotide
ITMI20031714A1 (en) 2003-09-05 2005-03-06 Gentium Spa FORMATIONS FOR ANTITUMORAL ACTION.
JP5014122B2 (en) * 2004-05-06 2012-08-29 アメリカ合衆国 Methods and compositions for the treatment of uveitis
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US20080009455A9 (en) * 2005-02-24 2008-01-10 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
WO2006094917A2 (en) * 2005-03-03 2006-09-14 Gentium Spa Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
CA2600036A1 (en) 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
CN102851295B (en) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll-like receptor regulatory oligonucleotide and application thereof
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
EP2278979A4 (en) * 2008-05-21 2012-09-26 Us Gov Health & Human Serv Method of treating pneumoconiosis with oligodeoxynucleotides
CN101643496B (en) * 2008-08-07 2015-09-09 长春华普生物技术有限公司 A kind of oligonucleotide with immune suppression function
US8053422B2 (en) 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
ES2572563T3 (en) 2008-12-09 2016-06-01 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
MX2011010050A (en) 2009-03-25 2011-12-14 Univ Texas Compositions for stimulation of mammalian innate immune resistance to pathogens.
CA2813413C (en) 2010-11-12 2018-03-06 Gentium S.P.A. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd)
CN102732610B (en) * 2012-03-23 2014-01-29 章晓联 Visualized detection probes and application thereof in tuberculosis rifampicin resistance mutation detection
SG11201408481UA (en) 2012-06-22 2015-01-29 Gentium Spa Euglobulin-based method for determining the biological activity of defibrotide
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN109451729B (en) 2016-06-08 2022-03-22 哈佛学院院长及董事 Engineered viral vectors reduce induction of inflammation and immune responses
CN112313018B (en) 2018-02-23 2023-05-30 国际测试技术有限责任公司 Novel materials and hardware for automatically cleaning flexible electronic web rolls
US11318550B2 (en) 2019-11-14 2022-05-03 International Test Solutions, Llc System and method for cleaning wire bonding machines using functionalized surface microfeatures
US11211242B2 (en) 2019-11-14 2021-12-28 International Test Solutions, Llc System and method for cleaning contact elements and support hardware using functionalized surface microfeatures

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US566153A (en) * 1896-08-18 Non-refillable bottle
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (en) 1981-10-23 1992-06-04 Molecular Biosystems Inc OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD.
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6288042B1 (en) * 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
PT772619E (en) 1994-07-15 2006-10-31 Univ Iowa Res Found OLIGONUCLEOTIDOS IMUNOMODULADORES
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
US7094766B1 (en) * 1995-06-06 2006-08-22 Trustees Of Boston University Use of locally applied DNA fragments
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP2001513776A (en) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders
DK1005368T3 (en) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (en) 1998-04-03 2007-04-15 Univ Iowa Res Found METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINE
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
EP1575504A4 (en) * 2002-08-01 2009-11-04 Us Gov Health & Human Serv Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
US8043622B2 (en) * 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
JP5014122B2 (en) * 2004-05-06 2012-08-29 アメリカ合衆国 Methods and compositions for the treatment of uveitis
EP2278979A4 (en) 2008-05-21 2012-09-26 Us Gov Health & Human Serv Method of treating pneumoconiosis with oligodeoxynucleotides
US8053422B2 (en) * 2008-12-04 2011-11-08 The United States Of America As Represented By The Department Of Health And Human Services Anti-cancer oligodeoxynucleotides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KRIEG ET AL.: "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 12631 - 12636, XP002161301 *
STUNZ ET AL.: "Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 32, 2002, pages 1212 - 1222, XP002965006 *
YAMADA ET AL.: "Effect of suppressive DNA on CpG-induced immune activation", JOURNAL OF IMMUNOLOGY, vol. 169, 2002, pages 5590 - 5594, XP002965004 *
ZEUNER ET AL.: "Reduction of CpG-induced arthritis by suppressive oligonucleotides", ARTHRITIS AND RHEUMATISM, vol. 46, no. 8, 2002, pages 2219 - 2224, XP002965005 *

Also Published As

Publication number Publication date
US8227438B2 (en) 2012-07-24
WO2003027313A2 (en) 2003-04-03
US8580944B2 (en) 2013-11-12
AU2002353783A8 (en) 2003-04-07
US9163244B2 (en) 2015-10-20
US20040248834A1 (en) 2004-12-09
US7514414B2 (en) 2009-04-07
US20120258144A1 (en) 2012-10-11
US20090208468A1 (en) 2009-08-20
US20140134233A1 (en) 2014-05-15
AU2002353783A1 (en) 2003-04-07

Similar Documents

Publication Publication Date Title
WO2003027313A3 (en) SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
WO2004012669A3 (en) Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
WO1999051259A3 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
CA2194761A1 (en) Immunomodulatory oligonucleotides
WO1999066879A3 (en) Systemic immune activation method using nucleic acid-lipid complexes
WO2004081021A3 (en) Oligonucleotide mimetics
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
PL350023A1 (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
CA2400377A1 (en) Method for treating ocular pain
WO2001039777A8 (en) Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2003084560A3 (en) Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
WO2005016241A3 (en) Synthetic chemokine receptor ligands and methods of use thereof
WO2002101073A3 (en) Aryl-benzimidazole compounds having antiinfective activity
WO2004082624A3 (en) Modafinil-based neurorehabilitation of impaired neurological function associated with injury
WO2002045742A8 (en) Lipoteichoic acid immunogenic compositions and methods of making and using thereof
WO2002070002A3 (en) Methods for regulation of immune responses to conditions involving mediator-induced pathology
IT1307007B1 (en) PRE-ASSEMBLED FRONT GROUP FOR VEHICLES.
IT1320540B1 (en) PRE-ASSEMBLED FRONT GROUP FOR VEHICLES.
WO1999059617A3 (en) Immunoregulator
MXPA03008634A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10489839

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP